ALV2 |
Katalog-Nr.GC63535
One-Click Copy Product Info
|
ALV2 ist ein potenter und selektiver Helios-Abbauer. ALV2 bindet CRBN mit einem IC50 von 0,57 μM. Helios ist der Zinkfinger-Transkriptionsfaktor, der einen stabilen Treg-Zell-PhÄnotyp in der Mikroumgebung des entzÜndlichen Tumors aufrechterhalten kann.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2438124-95-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ALV2 is an effective and selective degrader of Helios (IKZF2). ALV2 binds to CRBN with an IC50 of 0.57μM[1-2]. Helios is a zinc-finger transcription factor that maintains a stable regulatory T cell (Treg) phenotype within the inflammatory tumor microenvironment. ALV2 is used in research investigating the regulation of T cell function and the tumor immune microenvironment[3-4].
In vitro, ALV2 (1μM) was used to pre-treat human naive CD4+ T cells for 5 days, followed by activation with anti-CD3/CD28 antibodies for 2 days. This treatment significantly upregulated the production of CD25 and effector cytokines (such as IL-21 and IFNγ), and enhanced the ability of these cells to infiltrate inflammatory tissues in a human-synovial tissue-mouse chimeric model[5]. In RAW 264.7 murine macrophages infected with Salmonella for 1 hour, ALV2 (10μM; 24-hour treatment) significantly reduced the secretion of tumor necrosis factor-alpha (TNF-α)[6].
In vivo, in a mouse model with the humanized CrbnI391Vgenotype, administration of ALV2 via intraperitoneal injection (100mg/kg; twice daily; for 7 days) significantly reduced the protein levels of Helios (IKZF2) in splenic CD4+ FoxP3+ regulatory T cells (Tregs), without affecting Ikaros (IKZF1) levels[7].
References:
[1] Zhang Y, Li L, Xu J, et al. A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders. Molecules (Basel, Switzerland). 2026 Jan;31(3):459.
[2] Słabicki M, Park J, Nowak RP, et al. Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Molecular Cell. 2025 Aug;85(16):3184-3201.e14.
[3] Xue F, Zhang M, Li S, et al. SE(3)-equivariant ternary complex prediction towards target protein degradation. Nature Communications. 2025 Jul;16(1):5514.
[4] Chen Z, Dhruv H, Zhang X, et al. Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy. Nature Communications. 2025 May;16(1):4095.
[5] Zhang H, Jadhav RR, Cao W, et al. Aging-associated HELIOS deficiency in naive CD4+ T cells alters chromatin remodeling and promotes effector cell responses. Nat Immunol. 2023 Jan;24(1):96-109.
[6] Santelices J, Schultz A, Walker A, et al. Targeting deubiquitinating enzymes and ubiquitin pathway modulators to enhance host defense against bacterial infections. mBio. 2025 Oct 8;16(10):e0031225.
[7] Wang ES, Verano AL, Nowak RP, et al. Acute pharmacological degradation of Helios destabilizes regulatory T cells. Nat Chem Biol. 2021 Jun;17(6):711-717.
| Cell experiment [1]: | |
Cell lines | RAW 264.7 macrophages (a murine macrophage cell line) |
Preparation Method | RAW 264.7 macrophages were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. For high-throughput screening, cells were seeded into 96-well plates and infected with green fluorescent protein (GFP)-labeled SalmonellaTyphimurium UK-1. Following infection, cells were treated with ALV2 (10μM). |
Reaction Conditions | 10μM; 2 or 24 hours. |
Applications | ALV2 significantly reduced the secretion of TNF-α. |
| Animal experiment [2]: | |
Animal models | Humanized CrbnI391Vmice (a mouse model with a CRBN mutation that renders it permissive to IMiD-induced degradation). |
Preparation Method | Mice were treated with ALV2 (100mg/kg; twice daily for 7 days) via intraperitoneal injection. |
Dosage form | 100mg/kg; i.p.; twice daily for 7 days. |
Applications | ALV2 administration induced selective and significant degradation of the Helios (IKZF2) protein in splenic CD4+ FoxP3+ regulatory T cells (Tregs). |
References: | |
| Cas No. | 2438124-95-7 | SDF | |
| Formula | C26H26ClN5O5 | M.Wt | 523.97 |
| Löslichkeit | DMSO : 160 mg/mL (305.36 mM; Need ultrasonic)|Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9085 mL | 9.5425 mL | 19.0851 mL |
| 5 mM | 381.7 μL | 1.9085 mL | 3.817 mL |
| 10 mM | 190.9 μL | 954.3 μL | 1.9085 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)